Gastroenterology
Total Neoadjuvant Therapy Enables Organ Preservation Without Compromising Distant Control in pMMR/MSS Stage II–III Rectal Cancer: Insights from the NO-CUT Trial
The NO-CUT phase 2 trial shows that total neoadjuvant therapy (CAPOX-based TNT) followed by non-operative management for clinical complete responders achieved high 30‑month distant relapse‑free survival (95%) and enabled organ preservation
